trending Market Intelligence /marketintelligence/en/news-insights/trending/5DdQy28R3AJ7K7wVWzPASw2 content esgSubNav
In This List

Parnell Pharmaceuticals delisting from Nasdaq

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Parnell Pharmaceuticals delisting from Nasdaq

Australia-based Parnell Pharmaceuticals Holdings Ltd. will delist from the Nasdaq, effective Dec. 31.

The company said it believes that there has been an incongruence between the potential realizable value of Parnell's underlying assets and its share price as a Nasdaq-listed company, according to a news release.

The veterinarian pharmaceutical company anticipates its shares to be quoted on the OTC Pink open market following the delisting.